Closed Loop Medicine

Closed Loop Medicine is a clinical-stage digital therapeutics company pioneering a platform that integrates AI-driven, adaptive drug dosing with companion digital software. Its core strategy involves partnering with pharmaceutical companies to develop and commercialize personalized, combination prescription products, with an initial commercial and clinical focus on GLP-1 therapies for obesity and related conditions. The company has launched its first product in the U.S., secured key patents, and is actively building a pipeline in other chronic disease areas like hypertension and insomnia. It operates as a private, venture-backed firm leveraging regulatory designations for its software as a medical device.

Proprietary AI-based adaptive dosing platform combined with digital therapeutic software, designed to create personalized, dose-optimized drug + digital combination products.

Closed Loop Medicine competes in the digital therapeutics and personalized dosing space, which includes pure-play DTx companies (e.g., Pear Therapeutics, now defunct, but illustrating the sector's challenges), digital health platforms offering medication adherence support, and large tech companies (e.g., Google, Apple) exploring health data integration. Its specific focus on AI-driven, adaptive dosing for combination products with pharma partners is a differentiating niche, but it may face future competition from CROs or pharmacogenomics firms also aiming to personalize drug regimens.